David Bulmer has a BSc in pharmacology from the University of Manchester and a PhD in autonomic neuroscience from University College London. He is an Associate Professor and Part II Course Organiser in the Department of Pharmacology. David is also a Visiting Lecturer in Neuroscience at Queen Mary University of London (QMUL).
David has nearly 20 years experience researching in gastrointestinal pharmacology within both academia and industry, working to develop new drug treatments for IBS and IBD at GlaxoSmithKline before leaving on an MRC Skills Gap Fellowship to establish his own translation neuroscience lab focused on the use of human tissue to study visceral pain at QMUL. David left QMUL in 2017 to join the Department of Pharmacology, University of Cambridge.
David continues to enjoy strong links with industry, having research collaborations with Astra Zeneca, Sosei-Heptares and GlaxoSmithKline looking at novel pain treatments, and funding from leading charities such as Crohn's and Colitis UK, devoted to improving the lives of people with IBD.